Clinical Trial Search

Primary: Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period — 36; 93; 10; 23 Participants

Primary: The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28. — 976.6; 865.35 μmol∙h/L

Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — -0.065; 0.142; 0.173; 0.228 Liters — p=<0.001

Primary: Number of Participants With Adverse Events (AEs) According to Baseline Characteristics — 0; 1; 2; 3 participants

Primary: Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) — 41; 0 participants

Primary: Peak 6-minute Walk Distance — 366.0; 360.0; 21.6; 3.0 meters — p=0.00044

Primary: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) — 0.147; 0.212; 0.217; 0.278 Liters — p=0.208

Primary: Duodenal-related Complications — 13; 11; 8; 19 percentage of subjects

Primary: Response Rate — 22 percentage of participants

Primary: Overall Clinical Success (NDI, Fusion, Additional Surgical Procedures) — 5; 33; 28; 2 participants

Primary: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 30 — 7.52; -5.23 Millimeter

Primary: PASI 75 Response at Week 24 — 77.3; 60.3 Percentage of participants — p=<0.0001

Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score at Week 96 — 73.00; 18.24 Units on a scale

Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 9; 33 percentage of participants

Primary: Continuation Rates — 82; 78; 83 participants